X0306 4 2017-03-14 0 0001375151 ZOGENIX, INC. ZGNX 0001614780 Farfel Gail M C/O ZOGENIX, INC. 5858 HORTON STREET, STE. 455 EMERYVILLE CA 94608 0 1 0 0 EVP/Chief Development Officer Stock Option (Right to Buy) 10.20 2017-03-14 4 A 0 52500 0.00 A 2027-03-13 Common Stock 52500 52500 D Restricted Stock Units 2017-03-14 4 A 0 8750 0.00 A 2022-03-13 Common Stock 8750 8750 D The option was granted on March 14, 2017 and vests in a series of forty-eight (48) successive, equal monthly installments beginning on April 14, 2017, subject to the reporting person's continued employment with the Company on each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ZGNX common stock. The RSUs shall vest upon the approval by the U.S. Food and Drug Administration of the Company's New Drug Application for ZX008, provided such approval occurs within five years following the grant date, subject to the option recipient's continuous service to the Company on such vesting date. /s/ Thomas Doyle, Attorney-in-fact 2017-03-16